---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-042982"
form_type: "8-K/A"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T07:57:41.621277+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma regains Nasdaq minimum bid price compliance; reports 234% revenue growth in FY2024

## Summary
- Regained compliance after maintaining $1.00 bid price for 10 consecutive days through May 12, 2025.
- FY2024 revenue increased 234% YoY; operating expenses reduced 21%; EPS improved 77%.
- Secured three licensing partnerships with potential $7M upfront and up to $660M in milestones.
- Received approximately $0.5M in upfront payments in FY2025 year-to-date.
- Preliminary discussions underway with pharma and AI firms for co-developing Phase III-ready MDD and ADHD candidates.

## SEC filing metadata
- accession: 0001213900-25-042982
- form_type: 8-K/A
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390025042982/0001213900-25-042982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390025042982/ea0242092-8ka1_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-042982
- JSON: https://secwatch.observer/filing/0001213900-25-042982.json
- Plain text: https://secwatch.observer/filing/0001213900-25-042982.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.